Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:November 16, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Refractory Multiple MyelomaLast Updated:November 16, 2020Completed
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:April 14, 2017Completed
Condition(s):Relapsed Multiple Myeloma; Relapsed-Refractory Multiple MyelomaLast Updated:June 8, 2023Terminated
Condition(s):Recurrent Multiple Myeloma; Refractory Multiple MyelomaLast Updated:January 17, 2024Recruiting
Condition(s):Relapsed Cancer; Refractory Multiple Myeloma; Multiple MyelomaLast Updated:February 2, 2024Not yet recruiting
Condition(s):Multiple Myeloma in Relapse; Refractory Multiple MyelomaLast Updated:April 21, 2023Recruiting
Condition(s):Refractory Multiple MyelomaLast Updated:April 17, 2020Completed
Condition(s):Light Chain Deposition Disease; Refractory Plasma Cell MyelomaLast Updated:April 15, 2015Completed
Condition(s):Multiple Myeloma; Refractory Multiple Myeloma; Relapsed/Refractory Multiple MyelomaLast Updated:September 8, 2023Terminated
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:April 1, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.